

ASX ANNOUNCEMENT**14 October 2019****MedAdvisor Appoints Jeff Sherman to its Board**

MedAdvisor Limited (ASX: **MDR**, the **Company**), Australia's leading digital medication management company is pleased to announce the appointment of Mr Jeffrey Sherman to the Board of the Company. Mr Sherman has been appointed as the nominee director of HMS Holdings Corp. following their \$11m investment in the Company.

Mr Sherman, who is based in Texas USA; has more than 30 years of experience in the healthcare industry in key leadership positions. For the last 5 years Mr Sherman has been CFO and Treasurer of HMS Holdings Corp (NASDAQ:HMSY), a US\$3B Market Cap innovative health services company. Mr Sherman is responsible for financial operations, corporate strategy and development. Previously, Mr Sherman served as Executive Vice President and CFO of AccentCare, and Executive Vice President and CFO of LifePoint Hospitals Inc. Prior to that, he held senior finance and risk management positions at Tenet Healthcare Corporation.

Peter Bennetto, Chairman of the Board of MedAdvisor commented: *"We are delighted that Mr Sherman is joining the Board of MedAdvisor. His skills and experience in financial markets and US Healthcare will add further depth and talent to the already strong team that is leading MedAdvisor on its domestic and international expansion."*

---ENDS---

For more information

Simon Glover, CFO
MedAdvisor
Tel: +61 3 9095 3036
corporate@medadvisor.com.au

Jennifer Duraisingam
Corporate Communications Manager
Tel: +61 3 9095 3036
jenniferd@medadvisor.com.au

About MedAdvisor

MedAdvisor is a world class medication management platform that empowers users to more simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects users to tools and education materials from their local/preferred pharmacy. In Australia, MedAdvisor has connected over one million users through ~55% of Australian pharmacies and a network of thousands of GPs. MedAdvisor has recently partnered with Adheris in the US, Zuellig Pharma in Asia and launched into the UK on track to become one of the largest players in the global digital adherence market. In 2018, was recognised in the AFR Fast 100.